Bernstein raises target for Virbac stock from EUR 419.00 to EUR 426.00

Published on 10/02/2026 at 16:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Virbac margin hit 18.80 percent in first half of 2026, up 0.50 points. Virbac stock costs EUR 309.50 on October 2, 2026 versus EUR 306.50.

Geometrisches Bauhaus-Plakat mit dem Schriftzug PHARMA in kräftigen Farben — Bauhaus-Poster mit geometrischen Formen und Sektortext symbolisiert Virbac S.A., FR0000031577, Veterinärpharma-Industrie grafisch, Illustration mit AI erstellt.

Virbac (ISIN FR0000031577) was trading at EUR 309.50 at Lang & Schwarz on October 2, 2026 at 4:34 p.m. CEST, up 0.98 percent versus the EUR 306.50 prior close. The latest analyst action came on September 21, 2026, when Bernstein upgraded Virbac from Market-Perform to Outperform and raised its price target from EUR 419.00 to EUR 426.00, according to Investing.com.

Target rises as margins expand

Bernstein's new target stands 37.74 percent above the Lang & Schwarz price, using the EUR 309.50 intraday reference and the EUR 426.00 target. The upgrade reflects the animal-health group's margin expansion outlook and the contribution of its Supercharge product portfolio.

The valuation case rests on fresh first-half figures. Virbac reported EUR 768.0 million of revenue in the first half of 2026, up 7.40 percent at constant exchange rates and scope from the first half of 2025. Adjusted EBIT reached EUR 144.2 million, compared with EUR 135.0 million a year earlier, while the adjusted EBIT margin increased to 18.80 percent from 18.30 percent.

Revenue guidance stays at the upper end

Reuters reported on September 17, 2026, that Virbac confirmed its 2026 outlook at the upper end of its 5.50 percent to 7.50 percent revenue-growth range. The company said companion-animal revenue grew 10.00 percent and farm-animal revenue grew 6.70 percent in the first half, giving the guidance a broad operating base.

Consolidated net income rose 5.90 percent to EUR 87.1 million in the first half of 2026, according to the company release. The comparison matters because the higher margin and profit growth arrived alongside a 7.40 percent organic revenue increase, rather than from cost reductions alone.

Stock remains below its yearly high

At EUR 309.50, the Lang & Schwarz price was 20.54 percent below the EUR 389.50 52-week high and 4.21 percent above the EUR 297.00 low on October 2, 2026. The finance profile identifies Virbac as a Healthcare company in the Drug Manufacturers - General industry, while its Euronext Paris listing belongs to the SBF 120.

For investors, the central tension is visible in the gap between the EUR 426.00 analyst target and the current EUR 309.50 reference price: the target implies a 37.74 percent premium, while the stock remains materially below its yearly high. Price data show a modest intraday gain of 0.98 percent rather than a move large enough to establish a new short-term direction.

Virbac stock and the analyst target

Virbac stock was trading at EUR 309.50 at Lang & Schwarz on October 2, 2026 at 4:34 p.m. CEST, versus the EUR 306.50 prior close of October 1, 2026. The further course of trading is shown by the continuously updated real-time quote of Virbac stock.